PharmaCorp Rx Inc. PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 99.83% | 150.38% | 259.44% | 1,131.88% | 4,557.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.83% | 150.38% | 259.44% | 1,131.88% | 4,557.93% |
| Cost of Revenue | 98.87% | 148.36% | 247.75% | 1,074.37% | 4,178.50% |
| Gross Profit | 101.31% | 153.55% | 278.73% | 1,230.18% | 5,299.58% |
| SG&A Expenses | 93.22% | 122.78% | 143.64% | 142.46% | 333.49% |
| Depreciation & Amortization | 96.95% | 135.65% | 222.56% | 684.86% | 2,700.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.61% | 137.29% | 197.35% | 386.38% | 862.50% |
| Operating Income | -46.83% | -29.60% | 23.30% | 88.40% | 27.43% |
| Income Before Tax | -191.72% | -69.83% | 28.89% | 114.87% | 77.00% |
| Income Tax Expenses | 76.28% | 33,880.00% | 650.72% | 24,675.00% | 56,800.00% |
| Earnings from Continuing Operations | -148.36% | -144.08% | -31.42% | 108.08% | 63.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -680.71% | -374.57% | -263.71% | 5,000.00% | 1,741.67% |
| Net Income | -206.13% | -164.40% | -41.48% | 108.42% | 65.58% |
| EBIT | -46.83% | -29.60% | 23.30% | 88.40% | 27.43% |
| EBITDA | 31.00% | 30.71% | 66.89% | 127.27% | 50.03% |
| EPS Basic | -137.04% | -9.88% | 52.66% | 103.41% | 89.89% |
| Normalized Basic EPS | -288.89% | 12.24% | 70.37% | 106.56% | 94.61% |
| EPS Diluted | -132.14% | -9.76% | 52.07% | 103.07% | 89.51% |
| Normalized Diluted EPS | -250.00% | 14.00% | 69.44% | 106.01% | 94.01% |
| Average Basic Shares Outstanding | 31.99% | 38.08% | 63.25% | 124.22% | 299.47% |
| Average Diluted Shares Outstanding | 33.71% | 37.71% | 65.81% | 127.98% | 306.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |